Magnussen P, 2003. Treatment and re-treatment strategies for schistosomiasis control in different epidemiological settings: a review of 10 years’ experiences. Acta Trop 86 :243–254.
Engels D, Chitsulo L, Montresor A, Savioli L, 2002. The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Trop 82 :139–146.
World Health Organization, 2002. Prevention and control of schistosomiasis and soil-transmitted helminthiasis. World Health Organ Tech Rep Ser 912.
Doenhoff MJ, Kusel JR, Coles GC, Cioli D, 2002. Resistance of S. mansoni to praziquantel: is there a problem? Trans R Soc Trop Med Hyg 96 :465–469.
Cioli D, 1998. Chemotherapy of schistosomiasis an update. Parasitol Today 14 :418–422.
Green DA, 1993. Gold, frankincense, myrrh, and medicine. N C Med J 54 :620–622.
Michie CA, Cooper E, 1991. Frankincense and myrrh as remedies in children. J R Soc Med 84 :602–605.
Sheir Z, Amira AN, Massoud A, Salama O, Badra GA, El-Shennawy H, Hassan N, Hammad SM, 2001. A safe, effective, herbal antischistosomal therapy derived from myrrh. Am J Trop Med Hyg 65 :700–704.
Badria F, Abou-Mohamed G, El-Mowafy A, Masoud A, Salama O, 2001. Mirazid: a new schistosomicidal drug. Pharmaceut Biol 93 :127–131.
Talaat M, El Ayyat A, Sayed HA, Miller FD, 1999. Emergence of Schistosoma mansoni infection in upper Egypt: the Giza governorate. Am J Trop Med Hyg 60 :822–826.
Barakat R, Farghaly A, El Masry AG, El Sayed MK, Hussein MH, 2000. The epidemiology of schistosomiasis in Egypt: patterns of Schistosoma mansoni infection and morbidity in Kafr El Sheikh. Am J Trop Med Hyg 62 :21–27.
Utzinger J, N’Goran EK, N’Dri A, Lengeler C, Tanner M, 2000. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop Med Int Health 5 :771–778.
Picquet M, Vercruysse J, Shaw DJ, Diop M, Ly A, 1998. Efficacy of praziquantel against Schistosoma mansoni in northern Senegal. Trans R Soc Trop Med Hyg 92 :90–93.
Jordan B, Webb G, 1982. Epidemiology: Jordan, P, Webb, G, Goddard M, eds. Schistosomiasis, Epidemiology, Treatment and Control. London: Heinmann Medical Books, 24–242.
Ferrari MLA, Coelho PMZ, Antunes CMF, Tavaes CAP, Da-Cunha AS, 2003. Efficacy of oxamniquine and praziquantel in the treatment of S. mansoni infection: a controlled trial. Bull World Health Organ 81 :190–196.
Katz N, 1982. Double-blind clinical trial comparing praziquantel with oxamniquine in schistosomiasis mansoni. Rev Inst Med Trop, Sao Paulo. 24 :310–314.
da Silva LC, Sette H Jr, Christo CH, Saez-Alquezar A, Carneiro CR, Lacet CM, Ohtsuki N, Raia S, 1981. Treatment of hepatosplenic form of S. mansoni. Arzneimisselforschung 31 :601–603.
Thiong’o FW, Mbugua GG, Ouma JH, Sturrock RK, 2002. Efficacy of oxamniquine and praziquantel in school children from two S. mansoni areas. East African Med J 79 :29–33.
Doenhoff MJ, Modha J, Lambertucci JR, McLaren DJ, 1991. Immune dependence of chemotherapy. Parasitol Today 7 :16–18.
Botros S, William S, Ebeid F, Cioli D, Katz N, Day TA, Bennett JL, 2004. Lack of evidence for an antischistosomal activity of myrrh in experimental animals Am J Trop Med Hyg 71 :206–210.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||403||173||2|
This trial investigated the anti-schistosomal activity of mirazid in comparison with that of praziquantel in Schistosoma mansoni-infected Egyptian patients. The sample population was composed of 1,131 individuals (459 school children and 672 household members). Screening for S. mansoni was conducted using the standard Kato Katz technique. Four slides from a single stool sample were examined before treatment, and four slides per sample from stool samples obtained on three consecutive days were examined post-treatment. All positive eligible subjects were randomly assigned into two groups, the first received mirazid at a dose of 300 mg/day for three consecutive days, and the second received praziquantel at a single dose of 40 mg/kg. All treated subjects were examined 4–6 weeks post-treatment. Mirazid showed low cure rates of 9.1% and 8.9% in S. mansoni-infected school children and household members, respectively, compared with cure rates of 62.5% and 79.7%, respectively, in those treated with praziquantel. Therefore, we do not recommend mirazid as an agent to control schistosomiasis.